Accessibility Menu
Cartesian Therapeutics logo

Cartesian Therapeutics(NASDAQ) RNAC

Current Price$8.13
Market Cap$240.34MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2023)-75%
5 Year-86%
1 Year-31%
1 Month-15%
Cartesian Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 8.182026-07-20
Cartesian Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.21%USD 8.632026-07-13
1 month-15.06%USD 9.632026-06-18
3 month+18.38%USD 6.912026-04-21
Year to date+13.45%USD 7.212025-12-31
1 year-30.91%USD 11.842025-07-18
3 year-52.99%USD 17.402023-07-21
5 year-85.76%USD 57.452021-07-21
Since inception-74.52%USD 32.102023-11-14

Cartesian Therapeutics Financials at a Glance

Market Cap

$240.34MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.78M

Net Income (TTM)

-$151.77M

EPS (TTM)

-$5.80

P/E Ratio

-1.41

Dividend

$0.00

Beta (Volatility)

1.61 (High)

Price

$8.13

Volume

35,376.612

Open

$8.07

Previous Close

$8.18

Daily Range

$8.01 - $8.17

52-Week Range

$5.60 - $14.56

Estimated Earnings Date

Aug 6, 2026

RNAC News

Foolcom-Featured.png

Cartesian (RNAC) Q2 Revenue Drops 99%

Motley Fool Markets TeamAug 7, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cartesian Therapeutics

Cartesian Therapeutics helps people with autoimmune diseases.

It makes cell therapies to fix the immune system.

These treatments work in clinics without using harsh chemotherapy.

A New Kind of Medicine

  • Descartes-08: mRNA-based therapy that changes a patient's immune cells to treat muscle weakness; designed for clinic visits without chemotherapy.
  • NASP (SEL-212): Clinical-stage treatment for severe gout, a painful joint condition; licensed globally to Swedish Orphan Biovitrum AB.
  • mRNA Cell Platform: System using temporary genetic instructions to help patient cells fight disease; avoids permanent DNA changes.

Path to New Treatments

  • Merged with Old Cartesian in November 2023 to focus on clinical-stage mRNA cell therapies.
  • Entered a worldwide patent license with Biogen MA, Inc. in September 2023 for specific engineered T-cell products.
  • Achieved a $30 million milestone payment from Swedish Orphan Biovitrum AB in July 2024 for gout treatment progress.
  • Secured grant funding from the National Institute of Neurological Disorders and Stroke in June 2025 for autoimmune research.

What Makes Cartesian Stand Out

Cartesian produces its therapies using a proprietary mRNA platform designed for repeated outpatient dosing. This approach removes the need for pre-treatment chemotherapy common in traditional cell therapies.

The Latest Financial Numbers

  • Total revenues were $78,000 in Q1 2026, down 92.9% from $1.1 million in Q1 2025.
  • Net loss deepened to $39.2 million in Q1 2026, a 121.2% increase from $17.7 million in Q1 2025.
  • Free cash flow was negative $22.2 million in Q1 2026, an 8.4% improvement from negative $24.2 million in Q1 2025.
  • Cash and cash equivalents reached $118.6 million as of March 31, 2026.

The Big Picture

Cartesian has evolved from nanoparticle research into a clinical-stage developer of mRNA cell therapies for autoimmune diseases. Its strategy focuses on making advanced treatments more accessible through outpatient administration.

AI Generated • May 14, 2026

Industry

Biotechnology

Sector

Health Care

Employees

75

CEO

Carsten Brunn, PhD

Website

www.cartesiantherapeutics.com

Headquarters

Frederick, MD 21703, US

RNAC Financials

Key Financial Metrics (TTM)

Gross Margin

-620.96%

Operating Margin

-5144.51%

Net Income Margin

-8550.65%

Return on Equity

194.13%

Return on Capital

N/A

Return on Assets

-52.63%

Earnings Yield

-70.92%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$240.34MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

29.38M

Volume

35.38K

Avg. Volume

280.02K

Financials (TTM)

Gross Profit

-$11.02M

Operating Income

-$91.32M

EBITDA

-$158.55M

Operating Cash Flow

-$72.97M

Capital Expenditure

-$4.41M

Free Cash Flow

-$77.37M

Cash & ST Invst.

$118.64M

Total Debt

$11.86M

Cartesian Therapeutics Performance Analysis

Cartesian Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 110,777,00030.2%
20232023-12-31USD 26,004,000-76.5%
20242024-12-31USD 38,913,00049.6%
20252025-12-31USD 2,797,000-92.8%
Cartesian Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-72.9%
Q32025-09-3051.7%
Q42025-12-31109.5%
Q12026-03-31-91.8%
Cartesian Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 2.98N/A
20232023-12-31USD -49.76N/A
20242024-12-31USD -4.48-91.0%
20252025-12-31USD -5.0211.9%
Cartesian Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30188.2%
Q32025-09-30-330.0%
Q42025-12-31-150.7%
Q12026-03-3157.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$78.00K

-92.9%

Gross Profit

$78.00K

-92.9%

Gross Margin

100.00%

N/A

Market Cap

$240.34MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.20M

N/A

Employees

75

N/A

Net Income

-$39.18M

-121.2%

EBITDA

-$38.57M

-133.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$118.64M

-34.2%

Total Debt

$11.86M

-15.7%

Accounts Receivable

$261.00K

-85.2%

Inventory

$0.00

N/A

Long Term Debt

$7.67M

-26.0%

Short Term Debt

$4.19M

+13.0%

Return on Assets

-52.63%

N/A

Return on Invested Capital

-33.52%

N/A

Free Cash Flow

-$22.16M

+8.4%

Operating Cash Flow

-$22.14M

+4.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IVAInventiva S.A.
$4.51+2.09%
OBIOOrchestra BioMed Holdings, Inc.
$3.70-0.27%
EPRXEupraxia Pharmaceuticals Inc.
$6.50+4.17%
NAUTNautilus Biotechnolgy, Inc.
$1.70+0.59%

Trending Stocks

Symbol / CompanyPricePrice Chg
VIVKVivakor
$6.71+2.88%
NOKNokia
$10.71+0.06%
UTZUtz Brands
$14.11+0.89%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.41+0.06%

Questions About RNAC

What is the current price of Cartesian Therapeutics?

Cartesian Therapeutics is trading at $8.16 per share.

What is the 52-week range for Cartesian Therapeutics?

Over the past 52 weeks, Cartesian Therapeutics has traded between $5.60 and $14.56.

How much debt does Cartesian Therapeutics have?

As of the most recent reporting period, Cartesian Therapeutics reported total debt of $11.86M.

How much cash does Cartesian Therapeutics have on hand?

Cartesian Therapeutics reported $118.64M in cash and cash equivalents in its most recent financial results.

What is Cartesian Therapeutics’s dividend yield?

Cartesian Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services